From: Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens
Characteristicsa
Results
N
117
Karnofsky performance 100–80
91%
Lines of prior therapy: 0/1/2+ (%)
13/53/34
Prior therapy:
Gemcitabine mono/combination/5-FU-based (%)
45/55/43
Median OS (95% CI)
6.1 months (4.8–8.9)